• BX795: From PDK1 Signaling to TBK1 Insight

  2026-09-04

  BX795 is more than a potent PDK1 inhibitor: its activity against TBK1 and IKKε makes it a strategic tool for connecting PI3K/Akt/mTOR biology with IRF3-dependent innate immune signaling. This article translates the HBV–TBK1–autophagy findings into a practical framework for assay design, target attribution, and translational decision-making.

• Ibrutinib (PCI-32765) Research Workflow

  2026-09-04

  Build more interpretable B-cell assays with Ibrutinib (PCI-32765), combining covalent BTK inhibition with controlled dosing, washout, and signaling readouts. The workflow also shows how ATRX-stratified assay design from glioma drug-screen research can inform, but not replace, direct BTK studies.

• Methylprednisolone Sodium Succinate: Assay Design

  2026-09-03

  Methylprednisolone Sodium Succinate is examined here through an assay-design lens, connecting receptor biology, concentration-dependent immune effects, and endpoint selection. The article also extracts practical experimental lessons from palonosetron research without conflating evidence across therapeutic domains.

• Ibrexafungerp: From MIC Data to Model Design

  2026-09-03

  Ibrexafungerp, also known as MK 3118, connects glucan synthase biology with practical antifungal assay design. This evidence-focused guide explains how resistance genotype, assay standardization, acidic pH, and infection models shape interpretation.

• BX795: Mapping PDK1, TBK1, and IRF3 Signaling

  2026-09-02

  BX795 is a potent PDK1 inhibitor that also enables mechanistic analysis of TBK1–IRF3 signaling and autophagy. This guide explains how to separate kinase engagement, innate immune response modulation, and cancer cell growth inhibition in rigorous assays.

• Cl-Amidine: A Mechanism-First PAD4 Assay Guide

  2026-09-02

  Cl-Amidine trifluoroacetate salt provides a precise chemical probe for PAD4 enzyme activity assay design, histone citrullination studies, and immune-disease models. This guide connects PAD4 perturbation with ribotoxic-stress biology while clearly separating established evidence from testable cancer research hypotheses.

• SLC25A1, H3K27ac, and HNSCC Cisplatin Resistance

  2026-09-01

  A 2026 npj Precision Oncology study identifies SLC25A1 as a metabolic and epigenetic regulator of cisplatin resistance in head and neck squamous cell carcinoma. Its proposed SLC25A1–HSPD1–citrate–acetyl-CoA–H3K27ac pathway links cellular senescence with treatment failure and provides a rationale for evaluating SLC25A1 inhibition in resistant disease.

• Urolithin A for Reliable Cell Assays

  2026-09-01

  This scenario-driven guide explains how Urolithin A (SKU B7945) can be incorporated into cell viability, proliferation, and mitochondrial assays without overinterpreting metabolic readouts. It covers solvent compatibility, assay controls, cross-domain evidence from hepatic stellate cell research, and practical criteria for selecting reliable material.

• Standardized Whole-Blood Stimulation for Immunometabolism

  2026-08-31

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines defined immune challenges with metabolic intervention and cytokine measurement. The workflow preserves the complexity of fresh human blood while enabling more reproducible analysis of how metabolic pathways selectively shape immune responses.

• Lysosomal β-Galactosidase Staining Kit for Senescence

  2026-08-31

  The Lysosomal β-Galactosidase Staining Kit provides a microscopy-based readout of lysosomal acidic β-galactosidase activity for cell senescence staining. This guide explains how to interpret the blue X-gal signal in SLC25A1-driven cisplatin-resistance models without mistaking a lysosomal phenotype for standalone proof of senescence.

• Pomalidomide (CC-4047) in Cell Assays

  2026-08-30

  This scenario-driven guide explains how Pomalidomide (CC-4047), SKU A4212, can be integrated into viability, cytokine, proliferation, and erythroid progenitor workflows. It connects solvent handling and dose selection with multiple myeloma model heterogeneity and evidence-based interpretation.

• Procainamide Hydrochloride Research Workflows

  2026-08-29

  Procainamide Hydrochloride supports mechanistic studies spanning Nav1.5-dependent electrophysiology, inflammatory signaling, and epigenetic regulation. This practical guide connects assay design, formulation control, and a pregnancy-mouse cisplatin model to help researchers distinguish target activity from delivery or toxicity artifacts.

• SLC25A1, Senescence, and HNSCC Cisplatin Resistance

  2026-08-28

  A 2026 npj Precision Oncology study identifies SLC25A1 as a metabolic and epigenetic regulator of cisplatin resistance in head and neck squamous cell carcinoma. The work connects mitochondrial citrate transport, cytosolic acetyl-CoA, H3K27ac-dependent transcription, and cellular senescence, while positioning CTPI-2 as a preclinical strategy for testing SLC25A1 inhibition.

• MOG (35-55): From EAE Model to Translational Strategy

  2026-08-28

  MOG (35-55) is more than an experimental autoimmune encephalomyelitis inducer: it is a mechanistically informative platform for connecting antigen-specific neuroinflammation with therapeutic pathway discovery. This article examines how MOG (35-55) supports multiple sclerosis research, incorporates recent PARP7–STAT1/STAT2 findings, and offers practical guidance for designing more translationally useful studies.

• Procainamide Hydrochloride: An SPP1 Assay Strategy

  2026-08-27

  Procainamide Hydrochloride can support a phenotype-first research framework linking cardiac electrophysiology, innate immune signaling, and DNMT1 biology. This article translates a key SPP1 tumor-associated macrophage study into practical assay decisions while clearly separating validated findings from exploratory hypotheses.

8459 records 1/564 page Next 12345 下5页 Last page